Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Provided By GlobeNewswire
Last update: Aug 14, 2024
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation
80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial
Read more at globenewswire.com
